Profound Medical Corp.

106 articles about Profound Medical Corp.

• Profound Medical to to Participate in the 2023 Bloom Burton & Co. Healthcare Investor Conference

  4/19/2023

  Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that management will present an update on the Company’s business at the Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 26, 2023 at 10:00 a.m. Eastern Time at the Metro Toronto Convention Centre.

• Profound Medical to Release First Quarter 2023 Financial Results on May 10 – Conference Call to Follow

  4/19/2023

  Profound Medical Corp., a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2023 financial results after market close on Wednesday, May 10, 2023.

• Profound Medical Announces Fourth Quarter and Full Year 2022 Financial Results

  3/7/2023

  Profound Medical Corp., a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, reported financial results for the fourth quarter and full year ended December 31, 2022.

• Profound Medical to Present at the 43rd Annual Cowen Health Care Conference

  3/1/2023

  Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) today announced that its CEO and Chairman, Arun Menawat, will present an update on the Company’s business at the 43rd Annual Cowen Health Care Conference on Wednesday, March 8, 2023 at 9:10 a.m. Eastern Time.

• Profound Medical to Release Fourth Quarter and Full Year 2022 Financial Results on March 7 – Conference Call to Follow

  2/14/2023

  Profound Medical Corp. will announce its fourth quarter and full year 2022 financial results after market close on Tuesday, March 7, 2023.

• Profound Medical to Present at the 2022 Jefferies London Healthcare Conference

  11/8/2022

  Profound Medical Corp. announced that its CEO and Chairman, Arun Menawat, will present an update on the Company’s business at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 12:20 p.m. GMT.

• Profound Medical Announces Third Quarter 2022 Financial Results

  11/3/2022

  Profound Medical Corp., a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, reported financial results for the third quarter ended September 30, 2022.

• Profound Medical to Release Third Quarter 2022 Financial Results on November 3 – Conference Call to Follow

  10/13/2022

  Profound Medical Corp., a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2022 financial results after market close on Thursday, November 3, 2022.

• Four Year Follow-Up Data from Profound Medical’s TACT Pivotal Clinical Trial Confirm Durable and Stable Positive Trends Following Treatment with TULSA-PRO® of Men with Localized Prostate Cancer

  9/26/2022

  Profound Medical Corp. announced that updated results from the TACT (TULSA-PRO® Ablation Clinical Trial) pivotal study were presented for the first time this past weekend, on Saturday, September 24, 2022, by Laurence Klotz, M.D., FRCSC, CM, Professor of Surgery, University of Toronto and Sunnybrook Chair of Prostate Cancer Research, at the FOCAL 2022 Conference held in Los Angeles, CA.

• Profound Medical Announces Changes to its Commercial Organization to Support Continued Growth

  9/15/2022

  Profound Medical Corp. announced changes to its management team and structure designed to further position the Company for continued sales success and global growth.

• Profound Medical to Participate in September 2022 Investor Conferences

  9/6/2022

  Profound Medical Corp., a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced that management will participate in two investor conferences in September.

• Profound Medical Announces Second Quarter 2022 Financial Results

  8/4/2022

  Profound Medical Corp., a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, reported financial results for the second quarter ended June 30, 2022.

• Profound Medical to Release Second Quarter 2022 Financial Results on August 4 – Conference Call to Follow

  7/14/2022

  Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2022 financial results after market close on Thursday, August 4, 2022.

• Profound Medical to Participate in the Cowen 7th Annual FutureHealth Conference

  6/16/2022

  Profound Medical Corp. announced that its CEO and Chairman, Arun Menawat, will participate in a virtual panel discussion on Focused Ultrasound hosted by Joshua Jennings, M.D., Managing Director, Health Care - Medical Supplies & Devices, at Cowen’s 7th Annual FutureHealth Conference on Thursday, June 23, 2022 at 9:55 a.m. Eastern Time.

• Profound Medical to Participate in the 2022 Jefferies Global Healthcare Conference

  6/2/2022

  Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the 2022 Jefferies Global Healthcare Conference.

• TULSA-PRO® Was Front and Center at AUA2022

  5/17/2022

  Profound Medical Corp. announced that multiple clinical presentations and product demonstrations performed at the American Urological Association's 2022 Annual Meeting, which took place from May 13 – 16 in New Orleans, highlighted the ability of TULSA-PRO® to effectively and safely ablate physician-prescribed prostate tissue in an unrivaled variety of patients with prostate cancer and benign prostatic hyperplasia.

• Profound Medical to Participate in the 2022 Bloom Burton & Co. Healthcare Investor Conference

  4/25/2022

  Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the Bloom Burton & Co. Healthcare Investor Conference.

• Profound Medical to Release First Quarter 2022 Financial Results on May 9 – Conference Call to Follow

  4/18/2022

  Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2022 financial results after market close on Monday, May 9, 2022.

• Profound Medical Announces Fourth Quarter and Full Year 2021 Financial Results

  3/3/2022

  Profound Medical Corp., a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, reported financial results for the fourth quarter and full year ended December 31, 2021.

• Profound Medical to Participate in March 2022 Investor Conferences

  3/2/2022

  Profound Medical Corp., a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced that management will participate in two investor conferences in March.